NCT03789019View on ClinicalTrials.gov

BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 22, 2013

Primary Completion Date

July 29, 2016

Study Completion Date

July 29, 2016

Conditions
Metastatic Breast CancerStage IV Breast Cancer
Interventions
DRUG

BP-C1

BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

Trial Locations (7)

52000

Lampang Cancer Hospital, Lampang

Unknown

Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS), Moscow

Leningrad Regional Oncological Centre, Saint Petersburg

St. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary, Saint Petersburg

Siriraj Hospital, Mahidol University, Bangkok

Ubon Ratchanthani Cancer Hospital, Ubon Ratchathani

Udon Thani Cancer Hospital, Udon Thani

Sponsors

Lead Sponsor

Meabco A/S

Collaborators (1)

Meddoc
All Listed Sponsors
collaborator

Meddoc

OTHER

collaborator

Norwegian University of Life Sciences

OTHER

lead

Meabco A/S

INDUSTRY

NCT03789019 - BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment | Biotech Hunter | Biotech Hunter